{"nctId":"NCT02518191","briefTitle":"Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity","startDateStruct":{"date":"2015-09-01","type":"ACTUAL"},"conditions":["Breast Cancer"],"count":345,"armGroups":[{"label":"GnRHa group","type":"EXPERIMENTAL","interventionNames":["Drug: GnRHa"]},{"label":"None GnRHa group","type":"NO_INTERVENTION","interventionNames":[]}],"interventions":[{"name":"GnRHa","otherNames":["goserelin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Premenopausal women 18 to 49 years of age are eligible for enrollment\n* Patients have operable stage I to IIIA breast cancer for which treatment with adjuvant or neoadjuvant cyclophosphamide-containing chemotherapy was planned.\n* Eligible participants had taken no estrogens, antiestrogens, selective estrogen-receptor modulators, aromatase inhibitors, or hormonal contraceptives within the month before enrollment.\n* Human chorionic gonadotropin negative by urine test before entering the group.\n* Informed consent, understanding and compliance with the requirements of the study.\n* No significant chronic disease and any organ dysfunction.\n\nExclusion Criteria:\n\n* Exceptions were made for the use of hormonal contraception in women younger than 35 years of age that was discontinued before randomization.\n* Use of hormonal treatment for up to 2 months for the purposes of in vitro fertilization and cryopreservation of embryos or oocytes before randomization.\n* Patients with metastatic lesions or history of bilateral ovariectomy,ovarian radiation were excluded.\n* Patients received previous adjuvant endocrine therapy for breast cancer are not suitable to this trial.\n* Patients with uterine and/or adnexal diseases needing medical or surgical treatment are not suitable.\n* Allergic to active or inactive excipients of GnRHa is an exclusion criterion.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"49 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Premature Ovarian Insufficiency","description":"The serum levels of anti-MÃ¼llerian hormone (AMH) were measured using human AMH ELISA kit (11351, Biofine)). POI (premature ovarian insufficiency) was defined as AMH\\<0.5ng/mL in this study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]}]},{"type":"SECONDARY","title":"Survival Rate","description":"Overall Survival \\& Tumor Free Survival","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.17","spread":null},{"groupId":"OG001","value":"49.33","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":165},"commonTop":["fatique"]}}}